BOSTON, Nov. 16, 2026 — The Alzheimer’s Disease Data Initiative (AD Data Initiative) today launched the AlzInsights AI Collective to increase collaboration and speed up development of AI tools that could advance Alzheimer’s research. Unveiled at the Alzheimer’s Insights Summit 4 during the Clinical Trials on Alzheimer’s Disease (CTAD) conference, the Collective will bring together researchers and AI developers in five thematic working groups to build, validate and share reusable tools through AD Workbench, a secure, cloud-based data-sharing and research environment for scientists studying Alzheimer’s and related dementias. The AlzInsights AI Collective Catalyst, offering up to US$15 million in philanthropic funding, is launching alongside the Collective to support promising AI tools for the field.
The Collective builds on the momentum of the AD Data Initiative’s Alzheimer’s Insights AI Prize, which launched in August 2025 and drew more than 180 submissions from teams across 18 countries. Impressed by the quality of the projects, the AD Data Initiative doubled the total prize and in March 2026 awarded US$1 million each to two winners, Biomni-AD and Prima Mente. The AD Data Initiative also committed to continuing work with all 10 semifinalist teams to advance their solutions, and many of those teams have joined the Collective as founding members.
The launch comes at a critical moment for the field. More than 57 million people worldwide are living with Alzheimer’s or related dementias, and that number is projected to reach 153 million by 2050. Growing volumes of data, paired with AI methods that can analyze them at scale, could bring earlier diagnosis, better treatments and, one day, prevention within reach sooner.
“Alzheimer’s research and AI development are advancing rapidly at the same time, and there’s a unique opportunity to speed up the development of better tools to address Alzheimer’s disease,” said Niranjan Bose, interim Executive Director of the AD Data Initiative and Managing Director for Health & Life Sciences at Gates Ventures. “The AlzInsights AI Collective will build on the community we began creating through the Alzheimer’s Insights AI Prize, giving developers a place to work side by side with the researchers who know the science. The new AI Collective Catalyst will help move the field’s most promising AI tools forward faster. For the millions of families impacted by this disease, faster science means more reason for hope.”
The Collective will unite leading research groups and AI developers in five working groups that span the full path from discovery research to clinical trials:
- Data harmonization and knowledge integration: tools that combine and organize multimodal data from across studies to generate large datasets that enable research at scale.
- AI co-scientists and research agents: agentic systems that help formulate hypotheses, interrogate literature and data, and design analyses.
- Target discovery, drug repurposing and therapeutic design: systems that explore causal biology, help scientists prioritize targets, repurpose existing drugs and develop new therapeutics.
- Digital twins and virtual biology: in silico models of cells, pathways, patients and disease trajectories that let researchers test ideas before running live studies.
- Clinical translation, biomarkers and trials: tools that support smarter clinical trial design through patient stratification, biomarkers, progression prediction and trial matching.
Members will join a working group with teams tackling the same challenge, where they will exchange tools and methods to build on one another’s work instead of duplicating it. The AD Data Initiative plans to make tools developed through the working groups available to researchers via AD Workbench, which has more than 11,000 users from around the world.
The Catalyst, currently backed by Gates Ventures and West Health, is open to additional funders and will support AI tools with the potential to advance Alzheimer’s research and care delivery. Applications for Catalyst funding are expected to open in early 2027.
“Millions of families are waiting for better ways to detect, treat and care for Alzheimer’s disease,” said Tim Lash, President of West Health. “But a breakthrough molecule only matters if the model of care can deliver it. By contributing to the Catalyst, West Health is helping ensure promising AI tools are built from the start around how older adults and their families actually experience care.”
Developers and researchers interested in joining the Collective, and funders interested in supporting the Catalyst, can sign up for updates at www.alzheimersdata.org.
About the Alzheimer’s Disease Data Initiative
The Alzheimer’s Disease Data Initiative is on a mission to fundamentally transform Alzheimer’s disease and related dementias research. We offer researchers around the world secure data sharing and analytics tools and collaboration resources, all available to users at no cost. Led by a global coalition of academic, industry, government and nonprofit partners, the Alzheimer’s Disease Data Initiative empowers researchers by fostering research collaboration, enabling seamless access to multiple data sharing platforms, and unlocking important Alzheimer’s disease and related dementias (ADRD) datasets. Together, we are advancing scientific breakthroughs and accelerating discoveries in new diagnostics, treatments, and cures for ADRD. Discover available research resources on AD Workbench, or connect with us on alzheimersdata.org and LinkedIn.
For more information:
Alzheimer’s Insights AI Prize: https://www.alzheimersdata.org/accelerating-research/ai-explorations
AD Data Initiative: https://www.alzheimersdata.org
Media Contacts:
Grace Ren, on behalf of the AD Data Initiative
gren@globalhealthstrategies.com
Tiffany Yu, West Health